Vitamin D levels and presence of AMD are not associated

Article

Recent evidence suggesting a link between low vitamin D levels, delayed angiogenesis and reduced inflammatory response has been disproved.

Recent evidence suggesting a link between low vitamin D levels, delayed angiogenesis and reduced inflammatory response has been disproved in a study featured in Eye.

A cross-sectional clinical study led by Dr S. Golan, Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Israel, looked at 1045 members of the Maccabi Healthcare Services (MHS) with age-related macular degeneration (AMD) and 8124 patients who didn't have AMD. All participants had their Vitamin D levels taken during routine examinations between 2000 and 2008. The main outcome measure was Serum 25-OH vitamin D levels.

The findings demonstrated a mean ±SD level of 25-OH vitamin D of 24.1±9.41 ng/ml for AMD patients and 24.13±9.50 ng/ml for non-AMD patients. A third of AMD patients and 32.86% of the controls had vitamin D levels of under 16 ng/ml, and the proportions of examinations in which the vitamin D level was greater than 74 ng/ml were 0.19 and 0.14%, respectively.

The results suggest the study has disproved a recent investigation into the association between reduced vitamin D levels and presence of AMD.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.